<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TIMOPTIC- timolol maleate solution </strong><br>Aton Pharma, Inc.<br></p></div>
<h1>TIMOPTIC<span class="Sup">®</span><br>0.25% AND 0.5%<br>(TIMOLOL MALEATE OPHTHALMIC SOLUTION)<br>in OCUDOSE<span class="Sup">®</span> (DISPENSER)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<h1></h1>
<p class="First">PRESERVATIVE-FREE STERILE OPHTHALMIC SOLUTION in a Sterile Ophthalmic Unit Dose Dispenser</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Timolol maleate is a non-selective beta-adrenergic receptor blocking agent. Its chemical name is (-)-1-(<span class="Italics">tert</span>-butylamino)-3-[(4-morpholino-1,2,5-thiadiazol-3-yl)oxy]-2-propanol maleate (1:1) (salt). Timolol maleate possesses an asymmetric carbon atom in its structure and is provided as the levo-isomer. The optical rotation of timolol maleate is:</p>
<table width="100%">
<col align="center" valign="middle" width="5%">
<col align="center" valign="middle" width="10%">
<col align="left" valign="middle" width="85%">
<tbody class="Headless"><tr class="Botrule First Last Toprule">
<td align="center">[α]</td>
<td align="center">25°<br>405 nm</td>
<td align="left">in 1.0N HCl (C = 5%) = –12.2° (–11.7° to –12.5°).</td>
</tr></tbody>
</table>
<p>Its molecular formula is C<span class="Sub">13</span>H<span class="Sub">24</span>N<span class="Sub">4</span>O<span class="Sub">3</span>S•C<span class="Sub">4</span>H<span class="Sub">4</span>O<span class="Sub">4</span> and its structural formula is:</p>
<p><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=15ca19c2-f28b-4703-aa23-5af265af9e8b&amp;name=timoptic-01.jpg"></p>
<p>Timolol maleate has a molecular weight of 432.50. It is a white, odorless, crystalline powder which is soluble in water, methanol, and alcohol. Timolol maleate is stable at room temperature.</p>
<p>Timolol maleate ophthalmic solution is supplied in two formulations: Ophthalmic Solution TIMOPTIC<a name="footnote-reference-1" href="#footnote-1" class="Sup">1</a> (timolol maleate ophthalmic solution), which contains the preservative benzalkonium chloride; and Ophthalmic Solution TIMOPTIC<a href="#footnote-1" class="Sup">1</a> (timolol maleate ophthalmic solution), the preservative-free formulation.</p>
<p>Preservative-free Ophthalmic Solution TIMOPTIC is supplied in OCUDOSE<a href="#footnote-1" class="Sup">1</a>, a unit dose container, as a sterile, isotonic, buffered, aqueous solution of timolol maleate in two dosage strengths: Each mL of Preservative-free TIMOPTIC in OCUDOSE 0.25% contains 2.5 mg of timolol (3.4 mg of timolol maleate). The pH of the solution is approximately 7.0, and the osmolarity is 252-328 mOsm. Each mL of Preservative-free TIMOPTIC in OCUDOSE 0.5% contains 5 mg of timolol (6.8 mg of timolol maleate). Inactive ingredients: monobasic and dibasic sodium phosphate, sodium hydroxide to adjust pH, and water for injection.</p>
<hr class="Footnoterule">
<dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">1</a></dt>
<dd>Registered trademark of ATON PHARMA, INC.<br>COPYRIGHT © 2009 ATON PHARMA, INC.<br>All rights reserved</dd>
</dl>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="section-3.1"></a><p></p>
<h2>Mechanism of Action</h2>
<p class="First">Timolol maleate is a beta<span class="Sub">1</span> and beta<span class="Sub">2</span> (non-selective) adrenergic receptor blocking agent that does not have significant intrinsic sympathomimetic, direct myocardial depressant, or local anesthetic (membrane-stabilizing) activity.</p>
<p>Beta-adrenergic receptor blockade reduces <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> in both healthy subjects and patients with heart disease. In patients with severe impairment of myocardial function, beta-adrenergic receptor blockade may inhibit the stimulatory effect of the sympathetic nervous system necessary to maintain adequate cardiac function.</p>
<p>Beta-adrenergic receptor blockade in the bronchi and bronchioles results in increased airway resistance from unopposed parasympathetic activity. Such an effect in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or other bronchospastic conditions is potentially dangerous.</p>
<p>TIMOPTIC (timolol maleate ophthalmic solution), when applied topically on the eye, has the action of reducing elevated as well as normal intraocular pressure, whether or not accompanied by <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>. Elevated intraocular pressure is a major risk factor in the pathogenesis of glaucomatous visual field loss. The higher the level of intraocular pressure, the greater the likelihood of glaucomatous visual field loss and optic <span class="product-label-link" type="condition" conceptid="381732" conceptname="Nerve injury">nerve damage</span>.</p>
<p>The onset of reduction in intraocular pressure following administration of TIMOPTIC (timolol maleate ophthalmic solution) can usually be detected within one-half hour after a single dose. The maximum effect usually occurs in one to two hours and significant lowering of intraocular pressure can be maintained for periods as long as 24 hours with a single dose. Repeated observations over a period of one year indicate that the intraocular pressure-lowering effect of TIMOPTIC (timolol maleate ophthalmic solution) is well maintained.</p>
<p>The precise mechanism of the ocular hypotensive action of TIMOPTIC (timolol maleate ophthalmic solution) is not clearly established at this time. Tonography and fluorophotometry studies in man suggest that its predominant action may be related to reduced aqueous formation. However, in some studies a slight increase in outflow facility was also observed.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="section-3.2"></a><p></p>
<h2>Pharmacokinetics</h2>
<p class="First">In a study of plasma drug concentration in six subjects, the systemic exposure to timolol was determined following twice daily administration of TIMOPTIC 0.5%. The mean peak plasma concentration following morning dosing was 0.46 ng/mL and following afternoon dosing was 0.35 ng/mL.</p>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="section-3.3"></a><p></p>
<h2>Clinical Studies</h2>
<p class="First">In controlled multiclinic studies in patients with untreated intraocular pressures of 22 mmHg or greater, TIMOPTIC (timolol maleate ophthalmic solution) 0.25 percent or 0.5 percent administered twice a day produced a greater reduction in intraocular pressure than 1, 2, 3, or 4 percent pilocarpine solution administered four times a day or 0.5, 1, or 2 percent epinephrine hydrochloride solution administered twice a day.</p>
<p>In these studies, TIMOPTIC (timolol maleate ophthalmic solution) was generally well tolerated and produced fewer and less severe side effects than either pilocarpine or epinephrine. A slight reduction of resting heart rate in some patients receiving TIMOPTIC (timolol maleate ophthalmic solution) (mean reduction 2.9 beats/minute standard deviation 10.2) was observed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Preservative-free TIMOPTIC in OCUDOSE is indicated in the treatment of elevated intraocular pressure in patients with <span class="product-label-link" type="condition" conceptid="381290" conceptname="Ocular hypertension">ocular hypertension</span> or open-angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
<p>Preservative-free TIMOPTIC in OCUDOSE may be used when a patient is sensitive to the preservative in TIMOPTIC (timolol maleate ophthalmic solution), benzalkonium chloride, or when use of a preservative-free topical medication is advisable.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="contraindications"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Preservative-free TIMOPTIC in OCUDOSE is contraindicated in patients with (1) bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>; (2) a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>; (3) severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (see <span class="Underline"><a href="#warnings">WARNINGS</a></span>); (4) <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>; (5) second or third degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>; (6) overt <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> (see <span class="Underline"><a href="#warnings">WARNINGS</a></span>); (7) <span class="product-label-link" type="condition" conceptid="198571" conceptname="Cardiogenic shock">cardiogenic shock</span>; or (8) <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any component of this product.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="warnings"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">As with many topically applied ophthalmic drugs, this drug is absorbed systemically.</p>
<p><span class="Bold">The same adverse reactions found with systemic administration of beta-adrenergic blocking agents may occur with topical administration. For example, severe respiratory reactions and cardiac reactions, including <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> due to <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span> in patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, and rarely <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> in association with <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, have been reported following systemic or ophthalmic administration of timolol maleate (see <span class="Underline"><a href="#contraindications">CONTRAINDICATIONS</a></span>).</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></h2>
<p class="First">Sympathetic stimulation may be essential for support of the circulation in individuals with diminished myocardial contractility, and its inhibition by beta-adrenergic receptor blockade may precipitate more severe failure.</p>
<p><span class="Italics">In Patients Without a History of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">Cardiac Failure</span></span> continued <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> of the myocardium with beta-blocking agents over a period of time can, in some cases, lead to <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>. At the first sign or symptom of <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, Preservative-free TIMOPTIC in OCUDOSE should be discontinued.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2"></a><p></p>
<h2>Obstructive Pulmonary Disease</h2>
<p class="First">Patients with <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (e.g., <span class="product-label-link" type="condition" conceptid="255841" conceptname="Chronic bronchitis">chronic bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4169883" conceptname="Emphysema">emphysema</span>) of mild or moderate severity, bronchospastic disease, or a history of bronchospastic disease (other than bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, in which TIMOPTIC in OCUDOSE is contraindicated [see <span class="Underline"><a href="#contraindications">CONTRAINDICATIONS</a></span>]) should, in general, not receive beta-blockers, including Preservative-free TIMOPTIC in OCUDOSE.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.3"></a><p></p>
<h2>Major Surgery</h2>
<p class="First">The necessity or desirability of withdrawal of beta-adrenergic blocking agents prior to major surgery is controversial. Beta-adrenergic receptor blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli. This may augment the risk of general anesthesia in surgical procedures. Some patients receiving beta-adrenergic receptor blocking agents have experienced protracted severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> during anesthesia. Difficulty in restarting and maintaining the heartbeat has also been reported. For these reasons, in patients undergoing elective surgery, some authorities recommend gradual withdrawal of beta-adrenergic receptor blocking agents.</p>
<p>If necessary during surgery, the effects of beta-adrenergic blocking agents may be reversed by sufficient doses of adrenergic agonists.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.4"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">Diabetes</span> Mellitus</h2>
<p class="First">Beta-adrenergic blocking agents should be administered with caution in patients subject to spontaneous <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> or to diabetic patients (especially those with labile <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>) who are receiving insulin or oral hypoglycemic agents. Beta-adrenergic receptor blocking agents may mask the signs and symptoms of acute <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.5"></a><p></p>
<h2><span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">Thyrotoxicosis</span></h2>
<p class="First">Beta-adrenergic blocking agents may mask certain clinical signs (e.g., <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>) of <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>. Patients suspected of developing <span class="product-label-link" type="condition" conceptid="138387" conceptname="Thyrotoxicosis">thyrotoxicosis</span> should be managed carefully to avoid abrupt withdrawal of beta-adrenergic blocking agents that might precipitate a <span class="product-label-link" type="condition" conceptid="133436" conceptname="Thyrotoxic crisis">thyroid storm</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="general"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Because of potential effects of beta-adrenergic blocking agents on blood pressure and pulse, these agents should be used with caution in patients with cerebrovascular insufficiency. If signs or symptoms suggesting reduced cerebral blood flow develop following initiation of therapy with Preservative-free TIMOPTIC in OCUDOSE, alternative therapy should be considered.</p>
<p><span class="product-label-link" type="condition" conceptid="437860" conceptname="Choroidal detachment">Choroidal detachment</span> after filtration procedures has been reported with the administration of aqueous suppressant therapy (e.g. timolol).</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.1"></a><p></p>
<h3>Angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span></h3>
<p class="First">In patients with angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, the immediate objective of treatment is to reopen the angle. This requires constricting the pupil. Timolol maleate has little or no effect on the pupil. TIMOPTIC in OCUDOSE should not be used alone in the treatment of angle-closure <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>"></a><a name="section-7.1.2"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></h3>
<p class="First">While taking beta-blockers, patients with a history of <span class="product-label-link" type="condition" conceptid="4019380" conceptname="Atopy">atopy</span> or a history of severe <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to a variety of allergens may be more reactive to repeated accidental, diagnostic, or therapeutic challenge with such allergens. Such patients may be unresponsive to the usual doses of epinephrine used to treat <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1.3"></a><p></p>
<h3><span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle Weakness</span></h3>
<p class="First">Beta-adrenergic blockade has been reported to potentiate <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> consistent with certain myasthenic symptoms (e.g., <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, and generalized <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>). Timolol has been reported rarely to increase <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span> in some patients with <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span> or myasthenic symptoms.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="section-7.2"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Patients should be instructed about the use of Preservative-free TIMOPTIC in OCUDOSE.</p>
<p>Since <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> cannot be maintained after the individual unit is opened, patients should be instructed to use the product immediately after opening, and to discard the individual unit and any remaining contents immediately after use.</p>
<p>Patients with bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, a history of bronchial <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, severe <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span>, <span class="product-label-link" type="condition" conceptid="4171683" conceptname="Sinus bradycardia">sinus bradycardia</span>, second or third degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">atrioventricular block</span>, or <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span> should be advised not to take this product. (See <span class="Underline"><a href="#contraindications">CONTRAINDICATIONS</a>.</span>)</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">Although TIMOPTIC (timolol maleate ophthalmic solution) used alone has little or no effect on pupil size, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span> resulting from concomitant therapy with TIMOPTIC (timolol maleate ophthalmic solution) and epinephrine has been reported occasionally.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="baba"></a><a name="section-7.3.1"></a><p></p>
<h3>Beta-adrenergic blocking agents</h3>
<p class="First">Patients who are receiving a beta-adrenergic blocking agent orally and Preservative-free TIMOPTIC in OCUDOSE should be observed for potential additive effects of beta-blockade, both systemic and on intraocular pressure. The concomitant use of two topical beta-adrenergic blocking agents is not recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.2"></a><p></p>
<h3>Calcium antagonists</h3>
<p class="First">Caution should be used in the coadministration of beta-adrenergic blocking agents, such as Preservative-free TIMOPTIC in OCUDOSE, and oral or intravenous calcium antagonists, because of possible atrioventricular conduction disturbances, <span class="product-label-link" type="condition" conceptid="439846" conceptname="Left heart failure">left ventricular failure</span>, and <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>. In patients with impaired cardiac function, coadministration should be avoided.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.3"></a><p></p>
<h3>Catecholamine-depleting drugs</h3>
<p class="First">Close observation of the patient is recommended when a beta blocker is administered to patients receiving catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> and/or marked <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, which may result in <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, or <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.4"></a><p></p>
<h3>Digitalis and calcium antagonists</h3>
<p class="First">The concomitant use of beta-adrenergic blocking agents with digitalis and calcium antagonists may have additive effects in prolonging atrioventricular conduction time.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.5"></a><p></p>
<h3>CYP2D6 inhibitors</h3>
<p class="First">Potentiated systemic beta-blockade (e.g., decreased heart rate, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>) has been reported during combined treatment with CYP2D6 inhibitors (e.g., quinidine, SSRIs) and timolol.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.6"></a><p></p>
<h3>Clonidine</h3>
<p class="First">Oral beta-adrenergic blocking agents may exacerbate the <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">rebound hypertension</span> which can follow the withdrawal of clonidine. There have been no reports of exacerbation of <span class="product-label-link" type="condition" conceptid="4221991" conceptname="Rebound hypertension">rebound hypertension</span> with ophthalmic timolol maleate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.3.7"></a><p></p>
<h3>Injectable epinephrine</h3>
<p class="First"><span class="Italics">(See </span><span class="Italics Underline"><a href="#<span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>">PRECAUTIONS, General, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span></a></span><span class="Italics">)</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">In a two-year oral study of timolol maleate administered orally to rats, there was a statistically significant increase in the incidence of adrenal <span class="product-label-link" type="condition" conceptid="4118993" conceptname="Pheochromocytoma">pheochromocytomas</span> in male rats administered 300 mg/kg/day (approximately 42,000 times the systemic exposure following the maximum recommended human ophthalmic dose). Similar differences were not observed in rats administered oral doses equivalent to approximately 14,000 times the maximum recommended human ophthalmic dose.</p>
<p>In a lifetime oral study in mice, there were statistically significant increases in the incidence of benign and malignant pulmonary tumors, benign uterine <span class="product-label-link" type="condition" conceptid="4187628" conceptname="Polyp">polyps</span> and mammary adenocarcinomas in female mice at 500 mg/kg/day (approximately 71,000 times the systemic exposure following the maximum recommended human ophthalmic dose), but not at 5 or 50 mg/kg/day (approximately 700 or 7,000 times, respectively, the systemic exposure following the maximum recommended human ophthalmic dose). In a subsequent study in female mice, in which post-mortem examinations were limited to the uterus and the lungs, a statistically significant increase in the incidence of pulmonary tumors was again observed at 500 mg/kg/day.</p>
<p>The increased occurrence of mammary adenocarcinomas was associated with elevations in serum prolactin which occurred in female mice administered oral timolol at 500 mg/kg/day, but not at doses of 5 or 50 mg/kg/day. An increased incidence of mammary adenocarcinomas in rodents has been associated with administration of several other therapeutic agents that elevate serum prolactin, but no correlation between serum prolactin levels and mammary tumors has been established in humans. Furthermore, in adult human female subjects who received oral dosages of up to 60 mg of timolol maleate (the maximum recommended human oral dosage), there were no clinically meaningful changes in serum prolactin.</p>
<p>Timolol maleate was devoid of mutagenic potential when tested in vivo (mouse) in the micronucleus test and cytogenetic assay (doses up to 800 mg/kg) and in vitro in a neoplastic cell transformation assay (up to 100 mcg/mL). In Ames tests the highest concentrations of timolol employed, 5,000 or 10,000 mcg/plate, were associated with statistically significant elevations of revertants observed with tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA100 (in seven replicate assays), but not in the remaining three <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span>. In the assays with tester <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strain</span> TA100, no consistent dose response relationship was observed, and the ratio of test to control revertants did not reach 2. A ratio of 2 is usually considered the criterion for a positive Ames test.</p>
<p>Reproduction and fertility studies in rats demonstrated no adverse effect on male or female fertility at doses up to 21,000 times the systemic exposure following the maximum recommended human ophthalmic dose.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.5.1"></a><p></p>
<h3>Teratogenic Effects</h3>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.5.1.1"></a><p></p>
<h4>Pregnancy Category C</h4>
<p class="First"><span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">Teratogenicity</span> studies with timolol in mice, rats and rabbits at oral doses up to 50 mg/kg/day (7,000 times the systemic exposure following the maximum recommended human ophthalmic dose) demonstrated no evidence of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span>. Although delayed fetal ossification was observed at this dose in rats, there were no adverse effects on postnatal development of offspring. Doses of 1000 mg/kg/day (142,000 times the systemic exposure following the maximum recommended human ophthalmic dose) were maternotoxic in mice and resulted in an increased number of fetal resorptions. Increased fetal resorptions were also seen in rabbits at doses of 14,000 times the systemic exposure following the maximum recommended human ophthalmic dose, in this case without apparent maternotoxicity.</p>
<p>There are no adequate and well-controlled studies in pregnant women. Preservative-free TIMOPTIC in OCUDOSE should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.6"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Timolol maleate has been detected in human milk following oral and ophthalmic drug administration. Because of the potential for serious adverse reactions from timolol in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.7"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.8"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">No overall differences in safety or effectiveness have been observed between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="adversereactions"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The most frequently reported adverse experiences have been burning and <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">stinging</span> upon instillation (approximately one in eight patients). </p>
<p>The following additional adverse experiences have been reported less frequently with ocular administration of this or other timolol maleate formulations:</p>
<p>BODY AS A WHOLE</p>
<p><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>.</p>
<p>CARDIOVASCULAR</p>
<p><span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span>, <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>, cerebral vascular <span class="product-label-link" type="condition" conceptid="440279" conceptname="Accident">accident</span>, <span class="product-label-link" type="condition" conceptid="374384" conceptname="Cerebral ischemia">cerebral ischemia</span>, <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">cardiac failure</span>, worsening of <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>, <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitation</span>, <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span>, <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="442774" conceptname="Intermittent claudication">claudication</span>, Raynaud's phenomenon, and <span class="product-label-link" type="condition" conceptid="4035643" conceptname="Cold extremities">cold hands</span> and feet.</p>
<p>DIGESTIVE</p>
<p><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>.</p>
<p>IMMUNOLOGIC</p>
<p><span class="product-label-link" type="condition" conceptid="257628" conceptname="Systemic lupus erythematosus">Systemic lupus erythematosus</span>.</p>
<p>NERVOUS SYSTEM/PSYCHIATRIC</p>
<p><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span>, increase in signs and symptoms of <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4009184" conceptname="Dream anxiety disorder">nightmares</span>, behavioral changes and <span class="product-label-link" type="condition" conceptid="432586" conceptname="Mental disorder">psychic disturbances</span> including <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, and <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>.</p>
<p>SKIN</p>
<p><span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span> and psoriasiform <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span> or <span class="product-label-link" type="condition" conceptid="140168" conceptname="Psoriasis">exacerbation of psoriasis</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">HYPERSENSITIVITY</span></p>
<p>Signs and symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and localized and generalized <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>.</p>
<p>RESPIRATORY</p>
<p><span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">Bronchospasm</span> (predominantly in patients with pre-existing bronchospastic disease), <span class="product-label-link" type="condition" conceptid="4256228" conceptname="Respiratory failure">respiratory failure</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal congestion</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> and <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infections</span>.</p>
<p>ENDOCRINE</p>
<p>Masked symptoms of <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span> in diabetic patients (see <span class="Underline"><a href="#warnings">WARNINGS</a></span>).</p>
<p>SPECIAL SENSES </p>
<p>Signs and symptoms of ocular irritation including <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, <span class="product-label-link" type="condition" conceptid="378425" conceptname="Blepharitis">blepharitis</span>, <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span>, discharge (e.g., crusting), foreign body sensation, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> and tearing, and <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eyes</span>; <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>; decreased corneal sensitivity; <span class="product-label-link" type="condition" conceptid="4105178" conceptname="Cystoid macular edema">cystoid macular edema</span>; <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span> including refractive changes and <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>; pseudopemphigoid; <span class="product-label-link" type="condition" conceptid="437860" conceptname="Choroidal detachment">choroidal detachment</span> following filtration surgery (see <span class="Underline"><a href="#general">PRECAUTIONS, General</a></span>); and <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>.</p>
<p>UROGENITAL</p>
<p><span class="product-label-link" type="condition" conceptid="4176725" conceptname="Retroperitoneal fibrosis">Retroperitoneal fibrosis</span>, decreased libido, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, and Peyronie's disease.</p>
<p>The following additional adverse effects have been reported in clinical experience with ORAL timolol maleate or other ORAL beta blocking agents, and may be considered potential effects of ophthalmic timolol maleate: Allergic: Erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> combined with aching and <span class="product-label-link" type="condition" conceptid="26711" conceptname="Chronic pharyngitis">sore throat</span>, <span class="product-label-link" type="condition" conceptid="437904" conceptname="Laryngeal spasm">laryngospasm</span> with <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>; Body as a Whole: Extremity <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, decreased exercise tolerance, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span>; Cardiovascular: Worsening of <span class="product-label-link" type="condition" conceptid="4109870" conceptname="Arterial insufficiency">arterial insufficiency</span>, <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span>; Digestive: <span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">Gastrointestinal pain</span>, <span class="product-label-link" type="condition" conceptid="197676" conceptname="Large liver">hepatomegaly</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, mesenteric <span class="product-label-link" type="condition" conceptid="4278217" conceptname="Arterial thrombosis">arterial thrombosis</span>, <span class="product-label-link" type="condition" conceptid="4148299" conceptname="Ischemic colitis">ischemic colitis</span>; Hematologic: Nonthrombocytopenic <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">purpura</span>; <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>; <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span>; Endocrine: <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">Hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">hypoglycemia</span>; Skin: <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span>, <span class="product-label-link" type="condition" conceptid="4280604" conceptname="Skin irritation">skin irritation</span>, increased <span class="product-label-link" type="condition" conceptid="4083855" conceptname="Abnormal pigment">pigmentation</span>, <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>; Musculoskeletal: <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span>; Nervous System/Psychiatric: <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span>, local <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, diminished concentration, reversible mental <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> progressing to <span class="product-label-link" type="condition" conceptid="4085823" conceptname="Catatonia">catatonia</span>, an acute reversible syndrome characterized by <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span> for time and place, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional lability</span>, slightly clouded sensorium, and decreased performance on neuropsychometrics; Respiratory: <span class="product-label-link" type="condition" conceptid="4167669" conceptname="Respiratory crackles">Rales</span>, <span class="product-label-link" type="condition" conceptid="4279071" conceptname="Obstruction of bronchus">bronchial obstruction</span>; Urogenital: Urination difficulties.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First">There have been reports of inadvertent overdosage with Ophthalmic Solution TIMOPTIC (timolol maleate ophthalmic solution) resulting in systemic effects similar to those seen with systemic beta-adrenergic blocking agents such as <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, and <span class="product-label-link" type="condition" conceptid="321042" conceptname="Cardiac arrest">cardiac arrest</span> (see also <span class="Underline"><a href="#adversereactions">ADVERSE REACTIONS</a></span>).</p>
<p>Overdosage has been reported with Tablets BLOCADREN<a href="#footnote-1" class="Sup">1</a> (timolol maleate tablets). A 30 year old female ingested 650 mg of BLOCADREN (maximum recommended oral daily dose is 60 mg) and experienced second and third degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>. She recovered without treatment but approximately two months later developed irregular heartbeat, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span>, faintness, increased pulse rate, and borderline first degree <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">heart block</span>.</p>
<p>An in vitro hemodialysis study, using <span class="Sup">14</span>C timolol added to human plasma or whole blood, showed that timolol was readily dialyzed from these fluids; however, a study of patients with <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> showed that timolol did not dialyze readily.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="doseadmin"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Preservative-free TIMOPTIC in OCUDOSE is a sterile solution that does not contain a preservative. The solution from one individual unit is to be used immediately after opening for administration to one or both eyes. Since <span class="product-label-link" type="condition" conceptid="4035976" conceptname="Sterility">sterility</span> cannot be guaranteed after the individual unit is opened, the remaining contents should be discarded immediately after administration.</p>
<p>Preservative-free TIMOPTIC in OCUDOSE is available in concentrations of 0.25 and 0.5 percent. The usual starting dose is one drop of 0.25 percent Preservative-free TIMOPTIC in OCUDOSE in the affected eye(s) administered twice a day. Apply enough gentle pressure on the individual container to obtain a single drop of solution. If the clinical response is not adequate, the dosage may be changed to one drop of 0.5 percent solution in the affected eye(s) administered twice a day.</p>
<p>Since in some patients the pressure-lowering response to Preservative-free TIMOPTIC in OCUDOSE may require a few weeks to stabilize, evaluation should include a determination of intraocular pressure after approximately 4 weeks of treatment with Preservative-free TIMOPTIC in OCUDOSE.</p>
<p>If the intraocular pressure is maintained at satisfactory levels, the dosage schedule may be changed to one drop once a day in the affected eye(s). Because of diurnal variations in intraocular pressure, satisfactory response to the once-a-day dose is best determined by measuring the intraocular pressure at different times during the day.</p>
<p>Dosages above one drop of 0.5 percent TIMOPTIC (timolol maleate ophthalmic solution) twice a day generally have not been shown to produce further reduction in intraocular pressure. If the patient's intraocular pressure is still not at a satisfactory level on this regimen, concomitant therapy with other agent(s) for lowering intraocular pressure can be instituted taking into consideration that the preparation(s) used concomitantly may contain one or more preservatives. The concomitant use of two topical beta-adrenergic blocking agents is not recommended. (See <span class="Underline"><a href="#baba">PRECAUTIONS, Drug Interactions, Beta-adrenergic blocking agents</a></span>.)</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Preservative-free Sterile Ophthalmic Solution TIMOPTIC in OCUDOSE is a clear, colorless to light yellow solution.</p>
<p>No. 814– Preservative-free TIMOPTIC, 0.25% timolol equivalent, is supplied in OCUDOSE, a clear low density polyethylene unit dose container. Each individual unit contains 0.2 mL of solution, and is available in a foil laminate overwrapped pouch as follows:</p>
<p><span class="Bold">NDC</span> 25010-814-66; 60 Individual Unit Doses.</p>
<p>No. 815– Preservative-free TIMOPTIC, 0.5% timolol equivalent, is supplied in OCUDOSE, a clear low density polyethylene unit dose container. Each individual unit contains 0.2 mL of solution, and is available in a foil laminate overwrapped pouch as follows:</p>
<p><span class="Bold">NDC</span> 25010-815-66; 60 Individual Unit Doses.</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-11.1"></a><p></p>
<h2>Storage</h2>
<p class="First">Store at room temperature, 15-30°C (59-86°F). Protect from freezing. Protect from light.</p>
<p>Because evaporation can occur through the unprotected polyethylene unit dose container and prolonged exposure to direct light can modify the product, the unit dose container should be kept in the protective foil overwrap and used within one month after the foil package has been opened.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12"></a><p></p>
<h1></h1>
<p class="First">Manuf. for:</p>
<p>ATON PHARMA<br>Lawrenceville<br>NJ 08648<br>USA</p>
<p>By: Laboratories Merck Sharp &amp; Dohme-Chibret<br>63963 Clermont-Ferrand Cedex 9, France</p>
<p>Issued February 2009</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-13"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 0.25% Carton</h1>
<p class="First">Rx only<br><span class="Bold">NDC</span> 25010-814-66</p>
<p><span class="Bold">TIMOPTIC<span class="Sup">®</span> in OCUDOSE<span class="Sup">®</span></span></p>
<p><span class="Bold">(TIMOLOL MALEATE<br>OPHTHALMIC SOLUTION)<br>(DISPENSER)</span></p>
<p><span class="Bold">0.25%</span></p>
<p><span class="Bold">Timolol Equivalent (Timolol Maleate 3.4 mg/mL)</span></p>
<p>60 x 0.2 mL UNIT DOSES</p>
<p>FOR TOPICAL APPLICATION IN THE EYE</p>
<p><span class="Bold">PRESERVATIVE-FREE STERILE</span><br>OPHTHALMIC SOLUTION</p>
<p><span class="Bold">ATON</span><br>PHARMA<br><span class="Bold">Manufactured for:<br>ATON PHARMA, INC., Lawrenceville, NJ 08648, USA</span></p>
<p>By: Laboratories Merck Sharp &amp; Dohme-Chibret<br>63963 Clermont-Ferrand Cedex 9, France<br>Made in France</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 0.25% Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=15ca19c2-f28b-4703-aa23-5af265af9e8b&amp;name=timoptic-02.jpg"></div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 0.5% Carton</h1>
<p class="First">Rx only<br><span class="Bold">NDC</span> 25010-815-66</p>
<p><span class="Bold">TIMOPTIC<span class="Sup">®</span> in OCUDOSE<span class="Sup">®</span></span></p>
<p><span class="Bold">(TIMOLOL MALEATE<br>OPHTHALMIC SOLUTION)<br>(DISPENSER)</span></p>
<p><span class="Bold">0.5%</span></p>
<p><span class="Bold">Timolol Equivalent (Timolol Maleate 6.8 mg/mL)</span></p>
<p>60 x 0.2 mL UNIT DOSES</p>
<p>FOR TOPICAL APPLICATION IN THE EYE</p>
<p><span class="Bold">PRESERVATIVE-FREE STERILE</span><br>OPHTHALMIC SOLUTION</p>
<p><span class="Bold">ATON</span><br>PHARMA<br><span class="Bold">Manufactured for:<br>ATON PHARMA, INC., Lawrenceville, NJ 08648, USA</span></p>
<p>By: Laboratories Merck Sharp &amp; Dohme-Chibret<br>63963 Clermont-Ferrand Cedex 9, France<br>Made in France</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 0.5% Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=15ca19c2-f28b-4703-aa23-5af265af9e8b&amp;name=timoptic-03.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TIMOPTIC 		
					</strong><br><span class="contentTableReg">timolol maleate solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:25010-814</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Timolol Maleate</strong> (Timolol) </td>
<td class="formItem">Timolol</td>
<td class="formItem">2.5 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Phosphate, Monobasic</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Phosphate, Dibasic</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:25010-814-66</td>
<td class="formItem">4  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">15  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">0.2 mL in 1 CONTAINER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019463</td>
<td class="formItem">11/05/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TIMOPTIC 		
					</strong><br><span class="contentTableReg">timolol maleate solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:25010-815</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>Timolol Maleate</strong> (Timolol) </td>
<td class="formItem">Timolol</td>
<td class="formItem">5.0 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Phosphate, Monobasic</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Sodium Phosphate, Dibasic</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>Sodium Hydroxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>Water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:25010-815-66</td>
<td class="formItem">4  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">15  in 1 POUCH</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">0.2 mL in 1 CONTAINER</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA019463</td>
<td class="formItem">11/05/1986</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Aton Pharma, Inc.
							(795419675)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Laboratories Merck Sharp &amp; Dohme - Chibret</td>
<td class="formItem"></td>
<td class="formItem">493743686</td>
<td class="formItem">MANUFACTURE</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 10/2011<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>0f32f82b-4e6e-4958-9124-f97451ae3e20</div>
<div>Set id: 15ca19c2-f28b-4703-aa23-5af265af9e8b</div>
<div>Version: 2</div>
<div>Effective Time: 20111027</div>
</div>
</div> <div class="DistributorName">Aton Pharma, Inc.</div></p>
</body></html>
